The Conversation (0)
Pediapharm announced it will hold a presentation and meet up with investors at the upcoming annual LD Micro Invitational.
Pediapharm (TSXV:PDP) announced it will hold a presentation and meet up with investors at the upcoming annual LD Micro Invitational.
As quoted in the press release:
Pediapharm’s mission is to bring to the Canadian market the latest innovative pediatric products from around the world with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from around the world, including North America and Europe. The Company’s innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique dual mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is currently under review with Health Canada.
“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”
Click here to read the full press release.
Source: www.accesswire.com
